Strs Ohio Invests $595,000 in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Strs Ohio purchased 26,800 shares of Kiniksa Pharmaceuticals valued at approximately $595,000 during the first quarter, reflecting significant institutional interest in the company.
• Insider trading activity included sales by COO Eben Tessari and CAO Michael R. Megna, with declines of 32.19% and 22.44% in their respective positions.
• Analysts are optimistic about Kiniksa Pharmaceuticals, with several price target increases, and an average rating of "Buy" with a price target of around $41.17.

Strs Ohio purchased a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 26,800 shares of the company's stock, valued at approximately $595,000.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $42,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $61,000. Institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider Ross Moat sold 3,523 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the transaction, the insider owned 9,415 shares of the company's stock, valued at approximately $332,443.65. This represents a 27.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares of the company's stock, valued at $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 561,371 shares of company stock worth $18,825,009. 53.48% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA traded up $0.66 during trading hours on Monday, hitting $36.08. 267,055 shares of the company's stock were exchanged, compared to its average volume of 655,288. The company's 50-day moving average price is $32.62 and its 200-day moving average price is $27.69. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $37.34. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 902.23 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on KNSA. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.